Oral Alendronate Treatment for Severe Polyostotic Fibrous Dysplasia due to McCune-Albright Syndrome in a Child: A Case Report

  • Aragão A
  • Silva I
N/ACitations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Polyostotic fibrous dysplasia (FD) associated to McCune-Albright Syndrome (MAS) often leads to fractures, deformities, and bone pain resulting in bad quality of life. Parenteral bisphosphonates have been used in children and adolescents to improve these symptoms with few adverse effects. We evaluated the response to oral Alendronate in a girl with severe MAS FD and observed improved quality of life with reduction of bone pain.

Cite

CITATION STYLE

APA

Aragão, A. L. A., & Silva, I. N. (2010). Oral Alendronate Treatment for Severe Polyostotic Fibrous Dysplasia due to McCune-Albright Syndrome in a Child: A Case Report. International Journal of Pediatric Endocrinology, 2010, 1–4. https://doi.org/10.1155/2010/432060

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free